<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357353</url>
  </required_header>
  <id_info>
    <org_study_id>156-20-FB</org_study_id>
    <nct_id>NCT04357353</nct_id>
  </id_info>
  <brief_title>Platelet Rich Plasma for Erectile Dysfunction: A Randomized Controlled Trial</brief_title>
  <official_title>Platelet Rich Plasma for Erectile Dysfunction: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of Study: This randomized controlled trial investigates the role that platelet rich
      plasma injections into the penis may play to improve erectile function in men with erectile
      dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility: Men with erectile dysfunction. Ages 50-80. International Index of Erectile
      Function score of mild (17-21/25) or moderate (8-16/25).

      Intervention and Evaluation:Men who consent to join the trial will be randomized to receive
      either a single injection of high or low WBC PRP or saline to the penis. All patients will
      have blood drawn in clinic the day of injection. Those randomized to either PRP arm will have
      their own blood prepared and separated into the PRP. This solution of their own blood will be
      injected back into the penis. Men will be evaluated monthly with International Index of
      Erectile Function questionnaire until 6 months and again at 12 months.

      Follow Up: Men will be seen again 1 month after the injections and then asked to complete the
      IIEF by phone or by electronic means in monthly until 6 months and then again at 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erectile Function Change</measure>
    <time_frame>Monthly until 6 months</time_frame>
    <description>The degree of change in erectile function measured by IIEF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Sexual Function</measure>
    <time_frame>Monthly until 6 months</time_frame>
    <description>The degree of change in erectile function measured by Sexual Encounter Profile</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Side Effects</measure>
    <time_frame>Monthly until 6 months</time_frame>
    <description>any side effects noted by men</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">267</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>All arms will have phlebotomy (blood drawn). This group will receive saline injection only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All arms will have phlebotomy (blood drawn). This group will receive low white cell count PRP injection only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All arms will have phlebotomy (blood drawn). This group will receive high white cell count PRP injection only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platelet rich fibrin</intervention_name>
    <description>Both high and low WBC content PRP will be used in the 2 experimental arms.</description>
    <arm_group_label>High PRP</arm_group_label>
    <arm_group_label>Low PRP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Sham Injection</intervention_name>
    <description>sham injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  history of mild to moderate erectile dysfunction measured by IIEF

        Exclusion Criteria:

          -  history or prostate cancer treatment (prostatectomy, radiation, brachytherapy)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only men suffer from erectile dysfunction</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Deibert, MD, MPJH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Deibert, MD, MPH</last_name>
    <phone>4025594292</phone>
    <email>christopher.deibert@unmc.edu</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>April 19, 2020</last_update_submitted>
  <last_update_submitted_qc>April 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Christopher Deibert</investigator_full_name>
    <investigator_title>Assistant Professor Urology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

